PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search
BNF Chapter
BNF Paragraph
Please select a BNF Chapter.
Search Results : Nausea and vomiting (pregnancy) (Domperidone - Nausea and vomiting (pregnancy))
Records returned : 15 (on 23 Nov 2024 at 09:32:40). Return to search results for ' Nausea and vomiting (pregnancy) '.
Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
04.06.00
Green (see narrative)
Formulations :
- Oral suspension
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Safety alert and cardiac side-effects.
2nd line treatment option but should not be prescribed for longer than 7 days.
04.02.01
04.06.00
Green
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
1st line treatment option.
04.06.00
Green
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
1st line treatment option.
04.06.00
Green
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
1st line treatment option.
This is a lower cost promethazine option for primary care but note difference in CKS recommended dose.
04.06.00
Green
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
1st line treatment option.
04.06.00
Green
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
1st line treatment option.
Green (see narrative)
Formulations :
- Buccal/sublingual
ASPH
RSFT
SASH
SABP
Primary Care
Important
An option for patients with swallowing difficulties
04.06.00
Green (see narrative)
Formulations :
- Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
An option for patients with swallowing difficulties
04.06.00
Green (see narrative)
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
2nd line treatment option. Should not be prescribed for longer than 5 days.
Green (see narrative)
Formulations :
- Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
2nd line treatment option. Should not be prescribed for longer than 5 days.
An option in patients with swallowing difficulties.
04.06.00
Green (see narrative)
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
2nd line treatment option. Should not be prescribed for longer than 5 days and not recommended in the first trimester.
Green (see narrative)
Formulations :
- Orodispersible films
ASPH
RSFT
SASH
SABP
Primary Care
Important
An option in patients with swallowing difficulties.
2nd line treatment option. Should not be prescribed for longer than 5 days and not recommended in the first trimester.
04.02.01
04.06.00
Green (see narrative)
Formulations :
- Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
An option for patients with swallowing difficulties.
Green (see narrative)
Formulations :
- Gastro-resistant tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Not a preferred 1st-line option. Use only after failure of at least one established 1st-line treatment options
04.06.00
Non Formulary
Formulations :
- Oral solution
- Oro-dispersible
ASPH
RSFT
SASH
SABP
Primary Care
Important
Orodispersible films are a more cost effective option than oral solution and orodispersible tablets.
For information about the icons and status values within this site, please refer to the keys below.
Icon/Links Key
NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq form to be completed
NICE
Traffic Light Status Key
Red
Amber
Green
Black
Amber Star
Green (see narrative)
Non Formulary
See Below
N/A
Blue
Green - Black
See narrative
Do not initiate in new patients